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Circulating tumor cells (CTCs) are found in the blood of patients with cancer. 
Although these cells are rare, they can provide useful information for chemotherapy. 
However, isolation of these rare cells from blood is technically challenging because 
they are small in numbers. An integrated microfluidic chip, dubbed as CTC chip, was 
designed and fabricated for conducting tumor cell isolation. As CTCs usually show  
multidrug resistance (MDR), the effect of MDR inhibitors on chemotherapeutic drug 
accumulation in the isolated single tumor cell is measured. As a model of CTC 
isolation, human prostate tumor cells were mixed with mouse blood cells and the label-
free isolation of the tumor cells was conducted based on cell size difference. The major 
advantages of the CTC chip are the ability for fast cell isolation, followed by multiple 
rounds of single-cell measurements, suggesting a potential assay for detecting the drug 
responses based on the liquid biopsy of cancer patients. 
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INTRODUCTION 
Circulating tumor cells (CTCs) were first described in 1869 by Thomas Ashworth who 
observed small numbers of cells in patient blood and that they resembled cells of the primary 
tumor.1 These cells may constitute the seeds for subsequent metastasis in different organs.1,2,3 
Although the nature of CTCs is not fully understood, these cells are reported to be drug resistant 
in some types of metastatic cancers (e.g., breast cancer, lung cancer, prostate cancer and ovarian 
cancer),4-10 especially showing multidrug resistance (MDR) due to the expression of ATP-binding 
cassette (ABC) transporters.11,12 These transporters include P-glycoprotein (P-gp or ABCB1), 
multidrug resistant protein-1 (MRP1 or ABCC1) and breast cancer resistant protein (BCRP or 
ABCG2), which cause active transport of chemotherapeutic drugs (i.e., daunorubicin or 
paclitaxel) out of the cancer cell, termed as drug efflux, and this ultimately reduces the 
effectiveness of chemotherapy.13,14 Administration of MDR inhibitors that block drug efflux 
mediated by MDR transporters in combination with chemotherapeutic drugs that kill the tumor 
cells have been explored as a potential treatment strategy.15  
Isolation of CTCs can be useful for personalized cancer chemotherapy, because CTCs can 
be clinically important for providing predictive information for the adjustment of the therapeutic 
schemes.16 Our vision is that drug accumulation measured on CTCs can provide reliable 
information for patients undergoing chemotherapy. However, a key limitation in the capture of 
CTCs is their extreme rarity in blood (as low as ~1-100 in 1 mL blood including 5x109 
erythrocytes or red blood cells and 7x106 leukocytes or white blood cells).17-20  
Currently, CellSearch™ is a CTC-based system to provide prognostic information for 
metastatic breast, prostate, and colon cancers.21-24 In this FDA-approved system, CTCs are 
immunomagnetically captured from 7.5 mL of blood using magnetic labels conjugated to an 
antibody against the epithelial cell adhesion molecule (or EpCAM) on the cells, and then 
fluorescently stained with labeled antibodies against epithelial cell-specific markers.25 While the 
system allows the CTCs to be remunerated for cancer prognosis, further cellular analysis cannot 
be applied because the CTCs are bound and fixed.26 
Recently, worldwide efforts have been made to develop efficient and reliable CTC isolation 
techniques such as flow cytometry.27,28 Furthermore, a wide variety of microfluidic techniques 
used to isolate CTCs have been reported, and the isolation methods are based on 
immunoaffinity,16,29-34 and immunomagnetic separation.35-37 The immuno-based methods depend 
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on the use of an immunological label that recognizes the EpCAM biomarker in order to identify 
the presence of CTCs. Therefore, there are some limitations in this immuno-label method as some 
CTCs, particularly those of metastatic nature, might undergo epithelial-to-mesenchymal transition 
(EMT) thereby losing the EpCAM marker and potentially go undetected.26, 38 
On the other hand, there are some microfluidic methods that are label-free for CTC 
isolation,38 namely dielectrophoresis-based separation,39-41 density-based separation,37 
deformability-based separation43 and size-based separation.44 The last method is successful in 
isolating rare cells because most epithelial cells such as CTCs have sizes in order of 15-25 μm, 
which are larger than red blood cells (6-8 μm) and white blood cells (8-14 μm).45  
In this paper, we designed and fabricated a microfluidic biochip (CTC chip) to isolate PCa 
among whole blood cells without the use of a label (i.e., EpCAM antibody), followed by multiple 
rounds of single-cell measurement. In our approach, the human prostate cancer cells (as a model 
of CTC) were mixed with mouse blood cells. After removal of red blood cells and plasma, the 
buffy coat (white blood cells) mixed with tumor cells was introduced into the CTC chip. Since 
the captured tumor cell had not been subjected to any immunoaffinity manipulations (i.e., 
antibody), the captured cell can be used for single-cell measurements such as the drug 
accumulation assay.46-48 This is an established assay used to measure the real-time effect of MDR 
inhibitors on accumulation of chemotherapeutic drugs (e.g., daunorubicin and labeled paclitaxel) 
in the same single prostate tumor cell.  
MATERIALS  AND METHODS 
CTC chip design 
An integrated microfluidic chip, dubbed the CTC chip, was designed by the L-Edit software 
(Tanners). As shown in Fig. 1, the layout of the glass chip (20 mm x 30 mm) consisted of two 
chambers: Chamber 1 containing the sideward openings, and Chamber 2 containing the cell 
retention structure and dielectrophoresis (DEP) electrodes. Reservoirs A, B, E served as the cell 
inlet, blood cell collector and waste reservoirs, respectively; Reservoir C was used to move cells 
from Chamber 1 to Chamber 2; Reservoir D was used for drug delivery in chamber 2. The 
Channels and chambers in the CTC chip were 40 μm deep, while the Reservoirs were 0.6 mm 
deep and 2.5 mm in diameter. The CTC chip was fabricated by the standard micromachining 
processes at CMC Microsystems (Kingston, ON, Canada). The process includes standard chip 
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cleaning, thin film deposition, photolithography, photoresist development, HF wet etching, 
reservoir forming, and chip bonding, as previously described.49 
As depicted in Fig. 1, Chamber 1 in the CTC chip includes the cross-flow filter, with 
sideward openings perpendicular to the main flow, for separating cells based on size 
differences.50 Mouse blood cells, which are of similar size as human blood cells, were mixed with 
human prostate cancer cells, and the cell mixture was then introduced to Reservoir A. Because of 
the small size (<15 μm) of blood cells, they can only pass through the sideward openings and be 
collected in Reservoir B. Thereafter, as soon as an isolated prostate cancer cell could be found, it 
was captured in Chamber 2. The dielectrophoresis (DEP) electrodes in Chamber 2 (Pt 180 nm/Ta 
20 nm) were used to capture the single-cell in a fixed location during drug accumulation 
measurement, when the drug was delivered from Reservoir D. 
 
FIG. 1. The CTC chip. (a) Image of the microchip consisting of channels filled with a blue food dye and of electrodes 
connected to electrical wires. (b) Layout of the microfluidic device showing Reservoir D used for drug delivery, and 
Reservoirs A & E served as the cell inlet and waste, respectively. Blood cells were collected in Reservoir B. Reservoir 
C was used to move the selected cell from Chamber 1 to Chamber 2. (c,d) Close-up images of the cross-flow 
microfilters in Chamber 1 in order to isolate prostate cancer cells among a large population of blood cells based on size 
difference. (e,f) Close-up images of the cell retention structure in Chamber 2 and three DEP electrodes located inside 
the structure to capture the prostate cancer cell, followed by drug accumulation measurement. Scale bar: 100 μm. 
 
 
5 
Reagents 
Daunorubicin (DNR), Oregon Green® 488-conjugated paclitaxel (OG-PTX), fumitremorgin 
C (FTC) and cyclosporine A (CsA) were purchased from Sigma-Aldrich (St Louis, MO, USA). 
RPMI 1460 medium, trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA) (0.025%), 
glutamine, penicillin/streptomycin (PEN/STR) and fetal bovine serum (FBS) were obtained from 
Life Technologies (Grand Island, NY). Hanks’ balanced salt solution (HBSS) was from 
Invitrogen Corp (Grand Island, NY, USA, USA). DNR and OG-PTX were dissolved in DMSO 
(Sigma-Aldrich) to make stock solutions of 350 μM and 300 μM, respectively. Similarly, stock 
solutions of CsA (500μM) and FTC (1 mM) were made in DMSO. Alexa Fluor® 488-labeled 
anti-human P-gp monoclonal antibody was purchased from AbD Serotec (MorphoSys UK Ltd, 
Oxford, UK) and diluted in HBSS (1:20 ratio), and it was used to recognize human prostate 
cancer cell that expressed P-gp. The Ficoll-Paque PLUS solution from GE Healthcare (Pittsburgh, 
PA, USA) was kindly provided as a gift by Dr. Naveed Gulzar at the Molecular biology and 
biochemistry (MBB), Simon Fraser University. 
Cell samples 
The prostate cancer (PCa) cell line, 22Rv1, obtained from ATCC, is an androgen 
independent human cell line and naturally express ABCG2.51,52 This PCa cell line was grown in 
RPMI 1460 supplemented with 10% FBS, 1% PEN/STR and 1% glutamine. For cell subculture, 
the cells were detached using trypsin-EDTA and re-seeded in fresh medium every 4 days. All 
cultures were maintained at 37 °C in a humidified 5% CO2 and 95% air incubator (NuAire). Prior 
to tumor cell isolation, the size of the cells was measured in order to determine the average sizes 
and the cells were counted using a hemocytometer. Mouse blood cells were obtained from the 
Animal Care Services at Simon Fraser University after ethical approval. 
On-chip HF etching in Chamber 1 to create the cross-flow microfilter 
On-chip HF etching has been previously reported to enlarge a channel to create a weir 
structure to retain a single cardiomyocyte.49 We performed on-chip HF etching to create the 
cross-flow microfilter in Chamber 1 in order to remove the small blood cells but not the big 
tumor cells. The spacing of the sideward openings was small enough to allow passing of the small 
blood cells (6-14 μm); whereas the large tumor cells (15-25 μm) did not even approach the 
sideward openings and leak through. Since the spacing smaller than 80 μm cannot be made by the 
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initial glass etching process used to create the 40 μm-deep channels, HF etching was conducted 
after the glass chip was bonded. Briefly, 12% HF solution was put into Reservoir A, which was 
close to Chamber 1. In order to prevent HF from reaching the DEP electrodes located in Chamber 
2 and destroying them, water was introduced from Reservoir C and the water flow allowed the 
HF solution to be localized in Chamber 1. After 90 min, HF was removed from the chip to stop 
etching, and then the sideward openings were examined under the microscope (Fig. 2). 
 
 
 
FIG. 2 Creation of sideward openings in the cross-flow 
microfilter in Chamber 1 inside a bonded glass chip. 
Images (top view) showing the microfilter: (a,b) before 
etching and (c,d) after etching. Scale bar: 50 μm. 
 
Buffy coat preparation using a Ficoll gradient 
A 2 mL sample of mouse blood was collected in tubes containing heparin as an 
anticoagulant. The white blood cells were isolated by centrifugation using a Ficoll gradient, 
according to the manufacturer's protocol (GE Healthcare, Pittsburgh, PA). Briefly, a diluted 
suspension of blood was layered over 3 mL of Ficoll-Paque solution in a 15 mL conical tube and 
centrifuged at 400 x g at 20 °C for 40 min. Afterwards, the top layer including plasma and 
platelets was removed, and the buffy coat that consisted of the white blood cells (see Fig. S1a in 
the Electronic Supplementary Material) was then transferred to a new 15-mL conical tube and re-
suspended with PBS. After being centrifuged at 500 x g for 15 min, the cell pellet was collected. 
Since it was pink in color, it contained residual red blood cells (Fig. S1b). A micropipette tip was 
dipped into the cell pellet to gently remove the red blood cells. Thereafter, the white blood cells 
were re-suspended in PBS, and centrifuged at 500 x g for 15 min. The cell pellet was washed one 
more time with PBS by spinning at 600 x g for 8 min (Fig. S1c). Cells were then re-suspended in 
RPMI-1460 medium (supplemented with 10% FBS and 1% PEN/STR and 1% glutamine). 
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Thereafter, mouse blood cells, which are of similar size as human blood cells, were mixed with 
human prostate cancer cells.  
Isolation of individual prostate tumor cells 
The prostate tumor cell (22Rv1) was isolated using the cross-flow microfilter in Chamber 
1. Prior to the CTC capture experiments, the channels and chambers were filled with culture 
medium solution (RPMI-1460 supplemented with 10% FBS). A cell sample containing a mixture 
of 22Rv1 cells and blood cells (in a ratio of 1:4000) was injected into the CTC chip from 
Reservoir A. Fig. 3 describes the separation of the 22Rv1 cell among blood cells. Once the mixed 
cell sample (22Rv1 cells + blood cells) entered the wide chamber region (Chamber 1), the larger 
22Rv1 cells continued their straight path by the primary flow (Fig. 3c), while smaller and lighter 
cells followed the sideward flow (Fig. 3c). Comparison of Fig. 3a (blood cells only) and Fig. 3b 
(22Rv1 cells only) confirmed that the smaller cells moved toward the sideward openings, while 
the larger 22Rv1 cell continued the straight trajectory in the middle of Chamber 1. This result 
suggested that the larger 22Rv1 cell did not reach the sideward openings regardless of the 
presence of blood cells (see Fig. S2  in the Electronic Supplementary Material for the movement 
of cancer cells when mixed with blood cells at different ratios). The observation is counter-
intuitive, but it is consistent with other studies that the contact of large cells (i.e. cell diameter > 
10 μm) with the channel sidewall is very limited. It is because the opposed force generated by the 
hydrodynamic lift moves the cells away from the wall, and the force is stronger when the cell size 
is larger.40,44,53  
For an actual CTC experiment, as soon as the 22Rv1 cells were observed in Chamber 1, 
they were guided toward Chamber 2 by manipulating the liquid flow using Reservoirs A, C and 
E. For instance, with the high liquid level at Reservoir A and the low liquid level at Reservoirs C 
and E, the 22Rv1 cells would leave Chamber 1. As soon as the cells were near Reservoir C, the 
liquid flow from it was increased to push the cell further toward the cell retention structure in 
Chamber 2. The flow process has been controlled manually, but this process can be automated 
with the proper assistance of vision control and valving.  
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FIG. 3 Separation of the prostate cancer cell among other blood cells. (a) The blood cells (WBCs+RBCs) alone moved 
toward each of the sideward openings, splitting into two positions at right and left sides. (b) After injecting 22Rv1 cells 
alone, these big cells kept their straight path to reach Chamber 2. (c) In a mixture of 22RV1 cell and blood cells, the 
WBCs+RBCs passed through the sidewards exits and went to Reservoir B; whereas the 22Rv1 cell moved to Chamber 
2. It took ~2 s, 4 s and 8 s for each RBC, WBC and 22Rv1 cell to pass through Chamber 1, respectively. The black, 
white and red line arrows represent the movements of 22Rv1, WBC and RBC, respectively. Scale bar: 200 μm. 
Dielectrophoresis electrodes to trap a single prostate cancer cell in Chamber 2 
The term dielectrophoresis (DEP) was first introduced by Herbert Pohl in the 1950’s to 
describe the behaviour of particles in non-uniform electrical fields.54 DEP force can be created in 
a non-uniform electric field to move particles.11,55,56 The DEP forces depend on factors such as 
cell membrane and cytoplasm electrical properties as well as cell size.57 When the DEP force and 
drag force that act on the cell reached equilibrium, the cell could be kept stationary. Based on this 
concept, we used DEP electrodes for single-cell trapping during fluorescent measurement. The 
proper frequency and magnitude of the alternating voltage have been optimized to retain the cell, 
but not damage it by high voltage.58 Therefore, 11.5 V (3 MHz) was applied between electrodes 1 
and 2 to keep the cell stationary during experiments. The DEP force was turned off at ~ 5 min 
after trapping the single tumor cell.  
On-chip drug measurement on isolated single prostate cancer cell 
After the cell was kept stationary, the medium solution was introduced into Reservoir D to 
make sure the cell is stationary before running the drug accumulation experiment. An optical 
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detection system was employed for simultaneous fluorescence measurement and bright-field 
imaging.48,59 The procedure for drug accumulation measurement has previously been reported.46-48  
Briefly, the anti-cancer drug (i.e., DNR or OG-PTX) was introduced via Reservoir D and 
drug accumulation of the anti-cancer drug was measured in the single-cell. In the next step, the 
MDR inhibitor (i.e., CsA and/or FTC) was introduced via Reservoir D, and drug accumulation 
was measured in the same cell. Adding MDR inhibitors increased drug accumulation in the cell, 
and then the single-cell fluorescence intensity was enhanced. DNR was first used for drug 
accumulation measurement as it has inherent fluorescence (λex= 470 nm; λem= 585 nm). 
Thereafter, paclitaxel that was fluorescently labelled by Oregon Green was examined (λex = 488 
nm; λem = 524 nm), since paclitaxel was the commonly used anti-cancer drug for prostate cancer 
treatment.  
Statistical analysis 
Data are presented as the mean ± SD (standard deviation). Statistical significance test was 
determined using the Student’s t-test. 
RESULTS AND DISCUSSION 
Prostate tumor cell isolation among blood cell 
The morphology and size of prostate tumor cells and blood cells (WBCs + RBCs) were 
examined first. Fig. 4a shows the residual RBCs, and Fig. 4b,c illustrate the WBCs containing 
residual RBCs after one and two washes with PBS, respectively. Fig. 4d depicts the prostate 
cancer cell-WBCs mixture injected into Reservoir A of the CTC chip. This is a model for the 
capture of CTCs in a condition of 1 CTC in 4000 WBCs, or 250 CTCs in 106 WBC.20 
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FIG. 4 Preparation of the mixture of 
tumor cells and blood cells. After 
isolating white blood cells through a 
Ficoll gradient, the cell pellet was 
resuspended in an appropriate medium 
solution. Images show the morphology 
and size of residual red blood cells only 
(a), of white and residual red blood 
cells after first PBS washing (b), of 
white blood cells after second PBS 
washing (c) and of prostate cancer 
(PCa) cell mixed with white blood cells 
(1:4000 ratio) (d). The first 3 images 
were taken on a slide; whereas the last 
image was taken in Reservoir A of the 
CTC chip. Scale bar: 50 μm. 
 
 
Fig. 5 shows the process for isolating the prostate tumor (PCa) cells among blood cells. 
Based on the small size of the blood cells, they were split into two directions and moved to the 
right and left side of the sideward openings in Chamber 1 (Fig. 5b2,3) and collected in waste 
Reservoir B. The PCa cell moved in the middle of Chamber 1 (Figs. 5b2,3 and 5c) without going 
near the sideward openings. Approximately 33 min after injecting the cell sample, the first PCa 
cell passed through the first channel, which connected Reservoir A to Chamber 1.  An additional 
4 min was taken to move the PCa cell from Chamber 1 to Chamber 2, followed by capturing the 
isolated PCa single-cell by the DEP electrodes in the cell retention structure. This is a process for 
cell capturing without the use of an immunoaffinity label and for subsequent single-cell 
measurement, a process not currently feasible by using conventional methods. 
We should point out that the concept of dielectric differences between cancer and normal 
cells has been used for separating cancer cells by DEP.60 In general, different cell types having 
various surface area and size characteristics exhibit different DEP frequency responses. 
Mammalian cell dielectric properties may be described theoretically by using a shell model, in 
which the cell is represented as a homogenous core (i.e., cytoplasm) surrounded by a thin 
homogenous shell. This model describes the perfectly smooth idealized cell. However, in reality, 
cells have surface morphological features on the lipid bilayer membrane that increase the cell 
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surface area as compared to the smooth idealized cell. These morphological features can be taken 
into account by introducing a fold factor (ϕ) to represent the ratio of actual membrane area to 
that of the idealized smooth shell. It has been reported that cancer cells have larger fold factors as 
well as larger radii (r) than both blood cells and normal cells of comparable origin.61,62 The DEP 
response of cancer and normal blood cells is expressed in terms of the reciprocal cell dielectric 
phenotype 1/(r.ϕ). As reported by Gascoyne et al., the parameter for prostate cancer cells and 
blood cells are 1.3-2.3 and 4.3-7.3, respectively.60 Therefore, the cell with a lower 1/(r.ϕ) value 
(e.g., tumor cell) will be attracted toward the electrode edge while cells of higher 1/(r.ϕ) value 
(e.g., normal blood cell) will be repelled. This phenomenon suggests that the cell dielectric 
phenotype should be a widely applicable physical attribute of cancer cells. Interestingly, it has 
also been reported that even if the cancer cells undergo size reduction after maintenance in 
suspension, as compared to their original size when normally grown in contact with other cancer 
cells, their fold factor still remain high. Therefore, even the cancer cells exhibits a similar size to 
blood cells, it is still possible to use DEP to isolate the cancer cells.63 Based on this concept, even 
if any white blood cell with similar size as the PCa cell passed through Chamber 2 in our CTC 
microchip, the blood cell could not be attracted toward the electrode edge and it would be washed 
away from the cell retention structure. In our hands, when only blood cells injected into the CTC 
microchip, the white blood cells that entered Chamber 2 were always repelled away from 
Electrode 1.   
The DEP process is selective for WBCs, but not for RBCs because of their cell surface 
charges.64-66 Therefore, when the number of residual RBCs is high, a pre-screening of RBCs by a 
high flow is needed. Moreover, since DEP-based separation has the best performance with a slow 
flow rate because the weak DEP forces have a less chance of trapping targeted cancer cells due to 
a stronger flow-induced force. However, with a decrease in the flow rate, the throughput 
decreases, and so a higher flow is required for pre-screening whenever it is possible. In our 
microchip, a single cancer cell took ~30 s to move along Chamber 1, but this time was longer by 
a reduced liquid flow when the cell moved from the entrance of Chamber 2 to the cell retention 
structure (~60 s). Therefore, pre-screening of RBCs at a higher flow rate is required, after which a 
slower flow rate is used to remove residual WBCs (~5%). 
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FIG. 5 Isolation of tumor cells from blood cells. (a) Images show different regions in the CTC chip (schematic shown 
in Figure 6.1b). (b1-9) Images to show isolation of the prostate cancer (PCa) cell among WBCs and RBCs, followed by 
capturing the cell inside the cell retention structure in Chamber 2. (c) Close-up image from b2 to show the direction of 
the PCa cell movement. (d) Close-up image from b9 to show the capture of the PCa cell near Electrode 1 for drug 
accumulation experiment. Scale bar: 50 μm. 
Drug accumulation study on single 22Rv1 cell 
Drug accumulation measurement was conducted in Chamber 2. In the first step, accumulation of 
the anticancer drug (i.e., DNR or OG-PTX) in the single 22Rv1 cell was measured in the absence 
of a MDR inhibitor. The 22Rv1 cells naturally express the ABCG2 transporter.51 As a well-
known ABCG2 substrate,67 DNR was readily pumped out of the cell and the initial accumulation 
of DNR was low. As shown in Fig. 6b-c, during data collection, the chip was shuttled left and 
right to allow measurement of the cell and the background, respectively.  
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FIG. 6  Drug accumulation 
measured in a single PCa cell. 
(a) The cellular fluorescence 
intensity due to accumulation 
of 35 μM DNR was measured 
in real time. The chip was 
shuttled (b) into and (c) out of 
the detection window (red box) 
to measure the cellular signal 
and background, respectively. 
An AC electric field of 11.5 V 
at 3 MHz was applied to 
capture the cell close to the top 
DEP electrode before running 
the experiment. The electric 
field was turned off after 5 min 
as the cell was stationary. 
 
The experiment was conducted using DNR at different concentrations (3.5, 7, 14, 35, 70, 
350 μM) in order to determine the reasonable initial signal of drug accumulation in the cell. This 
signal should be around 10 times higher than the noise, and not too high to allow for the room for 
fold-increase due to drug accumulation enhancement.  
As shown in Fig. 7a, the initial signal of DNR at the above 6 concentrations were 100±37, 
290±39, 260±41, 530±42, 550±47 and 1280±50 counts per second (cps), respectively. The initial 
accumulation signal obtained from DNR at 35 μM provided the optimal signal. Similarly, 
experiments were conducted on a single 22Rv1 cell by treating it with OG-PTX at different 
concentrations (0.3, 1.5, 3, 6, 30 μM). As shown in Fig. 7b, the initial signals of the OG-PTX 
were 60±48, 100±52, 500±55, 1300±56, 2900±72 cps, respectively. Therefore, the optimal 
fluorescence signal was obtained after treating the single cell with 3 μM of OG-PTX. Subsequent 
experiments were carried out with 35 μM of DNR or 3 μM of OG-PTX. Fig. 7c shows a single 
22Rv1 cell treated with only 35 μM of DNR for a long period of time, showing the cell has 
reached a saturated fluorescence level. A similar experiment was conducted on another single 
22Rv1 cell by adding only 3 μM of OG-PTX, indicating saturation in the fluorescence intensity 
(Fig. 7d). We should point out that the alternating voltage used for DEP capture did not alter the 
cell membrane and reduce the MDR pump activity as no further increase in drug accumulation 
was observed after treating these single cells in multiple times by the anticancer drug alone (see 
Fig. 7c-d).  
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FIG. 7 Optimization of DNR and OG-PTX concentrations for drug accumulation measurements. (a,b) The initial 
accumulation signal obtained from 35 μM of DNR and 3 μM of OG-PTX in 22Rv1 prostate cancer cells appeared to be 
reasonable. (c,d) Signal remained at the saturation level in the single 22Rv1 cells treated in multiple times with 35 μM 
of DNR alone (c) and 3 μM of OG-PTX only (d). 
 
Effect of FTC on DNR accumulation 
Since 22Rv1 cells highly express the ABCG2 transporter,51 adding FTC (as a specific 
ABCG2 inhibitor)68,69 should increase DNR accumulation, and single-cell fluorescence should be 
enhanced. As shown in Fig. 8a, a steady state or plateau of the drug accumulation signal, due to a 
balance of the drug uptake and efflux processes, was first obtained. With the addition of FTC, the 
steady state was disturbed, and the DNR accumulation increased instantly. The effectiveness of 
the MDR inhibitor was indicated by the fold-increase in fluorescence, which was defined as the 
ratio between the fluorescence signals of the inhibitor-blocked cell and that of the unblocked cell. 
As shown in Fig. 8a, adding FTC as a MDR inhibitor enhanced drug accumulation by 3.5±0.2 
fold (p<0.0001), as compared with the 1.3±0.2 fold (p>0.1) obtained in the negative control. The 
fold-increases obtained at different time points before and after adding FTC were also plotted in 
Fig. 8b. The value of 3.5±0.2 is comparable, if not better than, the literature value of 2.0-fold 
obtained in the accumulation of D-luciferin (another well-known substrate of ABCG2) in 22Rv1 
cells treated by FTC (25 μM), based on a time-consuming bioluminescence imaging 
experiment.
70 
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Fig. 8c shows the images of this MDR cell before experiment (bright-field observation), 
during DNR treatment (simultaneous red-light bright-field observation during fluorescence 
measurement), after adding DNR in the presence of FTC and after trypan blue treatment. Since 
the cell was not stained by trypan blue, it was viable even after drug accumulation and DEP force 
was applied to capture the cell. Therefore, the cell was not killed even though 35 μM of DNR was 
used to treat the cell, and the xenon arc lamp was used to excite the drug molecules in the cell. 
To understand how fast the reagents reach the cell trapped in the cell retention structure, an 
observation of Chamber 2 was performed during treatment of the single-cell with trypan blue. 
Fig. S3 shows the flow of trypan blue, demonstrating how the dye quickly flows in Chamber 2 to 
reach the cell (~4 s) (see Electronic Supplementary Material). This fast flow was consistent with 
the results of a recent simulation study about the liquid flow behavior in the cell retention 
structure.71 
Our real-time fluorescence drug accumulation experiments also allow us to obtain the 
kinetics of the MDR inhibitor effects, using a previously reported mono-exponential drug uptake 
model.49 The curve fitting analysis was performed on the normalized drug accumulation data, 
using SAS software (see Fig. S4 in the Electronic Supplementary material). Based on the curve 
fitting results (Table S1 and S2), the fold-increases for DNR and OG-PTX accumulations were 
determined to be 3.4±0.2 and 2.4±0.4, believed to be caused by the action of FTC on ABCG2-
mediated drug efflux in the 22Rv1 cell.  
 
FIG. 8 Drug accumulation in a single 22Rv1cell in the presence of FTC as a MDR inhibitor. (a) Fluorescence intensity 
of the cell treated with 35 μM DNR measured in real time. The drug accumulation enhanced after adding 40 μM of 
FTC (black curve). The bottom curve in red shows the signal remained at a saturation level for the single cell treated 
with DNR only (negative control). (b) The fold-increase determined at different time points showing enhancement of 
drug accumulation after adding FTC (black line), as compared to no enhancement in the negative control (red line). (c) 
The images show the cell before, during and after experiment, followed by trypan blue treatment. Scale bar: 20 μm. 
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Effective concentrations of MDR inhibitors (FTC and CsA) 
Although P-gp is weakly expressed in the normal prostate cells,72 its expression increases in 
the tumor epithelium,55 especially in androgen-independent prostate cancer.11 For instance, P-gp 
(ABCB1) was detected in 35% of cell samples collected from non-treated prostate cancer patients 
(Homma et al., 2007). On the other hand, the ABCG2 transporter has been found in androgen-
independent prostate carcinoma cells such as 22Rv1 cells,51 and it has reported that this MDR 
transporter might mediate drug resistance in the prostate cancer stem cells resistant to androgen 
therapy.73 Our drug accumulation experiments on 22Rv1 cells were evaluated using both FTC (as 
a ABCG2 inhibitor) and CsA (as a ABCB1 inhibitor). As shown in Fig. 9a (blue line), the 
fluorescence signal of 35 μM DNR in a 22Rv1 cell was 630±77 cps. After adding different 
concentrations of FTC (10, 20, 40, 80 μM), the signal was enhanced (1.9±0.2, 2.8±0.2, 4.7±0.2 
and 4.8±0.2 fold-increase, respectively). Similar experiments were performed by adding different 
concentrations of OG-PTX (1.4±0.2, 2.1±0.2, 2.6±0.2 and 2.7±0.2 fold-increase, respectively) 
(Fig. 9a: red line). Therefore, the optimal fluorescence signals were obtained after treating the 
single cells with both anticancer drugs in the presence of 40 μM of FTC. In a similar manner, 
experiments were performed on single cells to optimize the CsA concentration. As shown in Fig. 
9b (green line), after adding DNR (35 μM) in the presence of different concentrations of CsA 
(0.5, 2.5, 5, 10, 20 μM), the signal was enhanced by 1.4±0.2, 2.1±0.2, 3.2±0.2, 3.4±0.2, 3.6±0.2 
fold, respectively. Similar CsA experiment was conducted by single-cell accumulation of 3 μM 
OG-PTX, and the fold-increases were 1.5±0.2, 1.8±0.2, 2.7±0.2, 3.0±0.2, 3.1±0.2, respectively 
(Fig. 9b: violet line). Therefore, the optimal fluorescence signals was found to be 5 μM of CsA 
after treating the single cells with both anticancer drug in the presence of this P-gp inhibitor.  
We should point out that the half-saturation concentration for the effect of a MDR inhibitor 
on the steady-state accumulation level, termed as the half-maximal inhibitory concentration 
(IC50), can be determined by: 
                                                        

IC50 Ki  FI                                                            (1) 
where Ki is the intrinsic affinity of the inhibitor for P-gp at its inner leaflet on the cell 
membrane;74 FI represents fold-increase, which is the ratio of unblocked to blocked accumulation 
of drug. Litman et al. reported 0.50 μM as the mean Ki for the affinity of CsA for P-gp to DNR 
treatment, regardless of the cell lines.
74
 Based on this equation and the Ki value (0.5 μM), the 
half-maximal inhibitory concentration of pumping by P-gp (or IC50) of CsA was calculated based 
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on the highest fold-increase of 3.57, resulting in a value of 1.8 μM. This IC50 was comparable 
with 1 μM, as reported for CsA on prostate cancer cell line 22Rv1.75 We should point out that 
IC50 depends on the number of pumps present in the plasma membrane; therefore, IC50 is greater 
in more highly multidrug resistant cells. 
 
FIG. 9 Effective concentrations of MDR inhibitors for experiments on the 22Rv1 cells. (a) Use of FTC (10, 20, 40, 80 
μM) to enhance DNR accumulation in the single-cell  (blue line). Similar FTC experiments were conducted by the 
single-cell accumulation of OG-PTX (red line). The optimal fluorescence signal was obtained after treating the cell in 
the presence of 40 μM FTC. (b) Use of CsA (0.5, 2.5, 5, 10, 20 μM) to enhance DNR accumulation in the single cell 
(green line). Similar CsA experiments were conducted by the single-cell accumulation of OG-PTX (violet line). The 
optimal fluorescence signal was obtained after treating the cell in the presence of 5 μM CsA. 100 data point were 
proceeded for individual single cells. 
 
Effect of multiple MDR inhibitors on single prostate cancer cells 
One of the requirements for the effectiveness of chemotherapy is the sufficient accumulation 
of chemotherapeutic drug in cancer cells.76-78 Since MDR is due to the function of ABC 
transporters that reduce intracellular drug accumulation in the cells, we examined whether FTC 
and CsA could alter BCRP and P-gp activity and improve the retention of DNR and OG-PTX in 
single prostate cancer cells. In single 22Rv1 cells treated with DNR in the presence of FTC (Fig. 
10a: red line), the fold-increase remained steady over 3000 s for a value of 3.8±0.2. When CsA 
was used, an approximate 2.7±0.2 fold-increase was observed. Similar steady values were 
obtained after applying OG-PTX in the presence of same MDR inhibitors (Fig. 11a: red line for 
FTC and Fig. 11b: orange line for CsA) (3.1±0.2 and 3.0±0.2 fold-increase, respectively). 
However, when the inhibitor was removed at 2050 s, there was drop in drug accumulation, 
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showing a lower fold-increase. For instance, in the single-cell treated with OG-PTX, the 
fluorescence signal decreased right after the MDR inhibitors were removed (fold-increase 
dropped from 2.7±0.2 to 1.4±0.2 for FTC and from 2.7±0.2 to 1.3±0.2 for CsA) (Fig. 11a: blue 
line and Fig. 11b: violet line). On the other hand, after accumulation of DNR in the presence of 
MDR inhibitors, DNR was more effectively retained in the cells right after removal of MDR 
inhibitors (Fig. 10a: blue line and Fig. 10b: violet line), particularly for FTC (fold- increase 
dropped from 3.8±0.2 to 2.8±0.2 for FTC  and from 2.3±0.2 to 1.5±0.2 for CsA). 
The more effective retention of DNR can be explained by its intercalation between the bases 
of DNA and impairments of its synthesis in the cell nucleus.79 This means DNR may get 
aggregated in the nucleus to form clusters that are too big to pass out through the nuclear pores in 
a short time (~1 hr).76-78 Unlike DNR, OG-PTX’s site of action is in the cytoplasm, by stabilizing 
tubulin polymerization in it, ultimately interfering the cell division.80 Our results corroborate the 
notion that once DNR enters the cell, it may not be as easy as OG-PTX to be extruded from the 
cells once the MDR function is restored by removing the inhibitors.  
More experiments were performed on DNR accumulation in single MDR cells (n=6) using 
different inhibitors. Applying FTC, CsA and FTC + CsA produced fold-increases of 3.7±0.4, 
4.2±0.6, 4.9±0.7, respectively (Fig. 10c). Additional experiments on OG-PTX accumulation in 
six individual single cells with the above three MDR inhibitor treatments indicated similar results 
(2.7±0.4, 3.4±0.5, 3.7±0.6, respectively) (Fig. 11c). It should be pointed out that ABCB1 appears 
to be the main transporter for PTX, while DNR is the substrate of both ABCB1 and ABCG2 
transporters.81 Although there was an immediate decrease in drug accumulation after removing 
the MDR inhibitors, this signal decrease due to inhibitor loss could be compensated by adding 
CsA. We also found the treatment of FTC+CsA after treating with CsA enhanced further drug 
accumulation in the single cells. Although the inhibition mechanism of the combination of MDR 
inhibitors is not entirely clear, the simultaneous administration of MDR inhibitors has been 
reported. For instance, verapamil and CsA (as P-gp inhibitors) and MK571 (as a MRP1 inhibitor) 
have been reported to increase the intracellular levels of [3H]-labeled drug in leukemia cells only 
after co-administered simultaneously.82 
Although further enhancement in drug accumulation might occur, the averaged data did not 
show a significant difference. It was interesting to find that the further enhancement of drug 
accumulation due to treatment of FTC+CsA was observed in the single-cell experiments, but not 
in the averaged results when the number of experiments was insufficient. For instance, the 
 
19 
averaged results of several single-cell experiments did not result in the enhancement in a 
statistically significant manner (p>0.05). On the other hand, the p-values were less than 0.0001 
for the enhancement of DNR accumulation after treating the same single 22Rv1 cell with 
FTC+CsA, right after CsA treatment (Fig. 10d). In a similar manner, significant enhancement 
(p<0.0001) of OG-PTX accumulation was observed when real-time measurement was conducted 
(number of data points = 140) on the same single cell after CsA treatment (Fig. 11d). We believe 
that more repeated experiments are demanded to obtain a significant enhancement in the averaged 
results. However, the same single cell experiment has the power to reveal the change in a 
significant manner when conducted real-time on the same single cell. 
 
FIG. 10 Enhancement of DNR accumulation in single 22Rv1 cells due to ABCG2 and ABCB1 inhibitors. (a) Use of 
FTC (40 μM) to enhance accumulation of DNR (35 μM) in a single-cell (red line). Blue line shows signal decrease 
after removing FTC at 2050 s. No significant enhancement was observed (p>0.1) in single cells (green line) treated for 
4000 s with 35 μM of DNR alone (negative control). (b) Use of CsA (5 μM) to enhance cellular drug accumulation 
(orange line). Violet line indicates signal decrease after removing CsA at 2050 s. (c) Averaged results (n=6) of fold-
increase in DNR accumulation were observed after adding FTC, followed by CsA and combination of FTC+CsA. (d) 
The fold-increases after treating a single-cell with DNR in the presence of FTC, CsA and FTC+CsA (number of data 
points=140). 
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FIG. 11 Enhancement of OG-PTX accumulation in single 22Rv1 cells due to ABCG2 and ABCB1 inhibitors. (a) Use 
of FTC (40 μM) to enhance accumulation of OG-PTX (3 μM) in a single-cell (red line). Blue line indicates signal 
decrease after removing FTC at 2050 s. No significant enhancement was observed (p>0.1) in single cells (green line) 
treated for 4000 s with 3 μM of OG-PTX alone (negative control). (b) Use of CsA (5 μM) to enhance cellular drug 
accumulation (orange line). Violet line shows signal decrease after removing CsA at 2050 s. (c) Averaged results 
(n=6) of fold-increase in OG-PTX accumulation were observed after adding FTC, followed by CsA and combination 
of FTC+CsA. (d) The fold-increases after treating a single-cell with OG-PTX in the presence of FTC, CsA and 
FTC+CsA (number of data points=140). 
           
Comparison of drug accumulation in captured single prostate cancer cells and in normal white 
blood cells 
Multiple rounds of drug accumulation experiments were conducted on the single PCa cell 
isolated from blood cells. To ensure that the captured single-cell was indeed cancerous, anti-
human monoclonal P-gp antibody (anti-CD243) was introduced to detect P-gp on the 22Rv1 cell 
surface subsequent to drug accumulation experiments. Fig. 12a shows obvious enhancement in 
fluorescence intensity (at 585 nm) due to DNR accumulation in a 22Rv1 cell after undergoing 
various MDR inhibitors treatment (FTC, CsA and CsA + FTC) (i.e., 3.3±0.2, 4.5±0.2, 5.4±0.2 
fold-increase, respectively (p<0.0001). After washing the cell with HBSS (2x), anti-P-gp was 
applied and the fluorescence signal (524 nm) was found to increase. This result confirmed the cell 
was 22Rv1, but not a blood cell, since the cell was stained by the anti-Pgp antibody.  
On the other hand, in a similar experiment conducted on a white blood cell (WBC), the cell 
was not stained by the anti-Pgp antibody, indicating it was not a 22Rv1 cell (Fig. 12c). As for the 
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single-cell DNR accumulation measurement, the WBC demonstrated the behaviour of a non-
cancerous cell, i.e., the drug accumulation reached only at a much longer time and there was no 
enhancement by adding CsA. The accumulation of DNR in the WBC also led to its staining by 
trypan blue (Fig. 12f3). We should point out that this cell was examined when only blood cells 
but no cancer cells were used; therefore, the captured cell must be a WBC.  
Fig. 12b depicts the accumulation of OG-PTX in a single 22Rv1 cell, showing an obvious 
enhancement in fluorescence intensity (at 524 nm) due to various MDR inhibitor treatments 
(FTC, CsA and FTC + CsA) (i.e., 2.8±0.2, 4.4±0.2, 4.9±0.2 fold-increase, respectively 
(p<0.0001). After washing the cell, there was a drop in fluorescence intensity, indicating the 
removal of OG-PTX from the cell. Thereafter, anti-P-gp antibody was applied, and the 
fluorescence signal (524 nm) was enhanced, confirming that the cell was 22Rv1.   
 
 
FIG. 12 Anti-Pgp antibody 
binds to the 22Rv1 cells but 
not to white blood cell. (a) 
MDR inhibitors enhanced 
DNR accumulation on the 
captured single PCa cell. The 
fluorescence signal increased 
after adding P-gp antibody. 
(b) Similar results observed 
after treating another single 
PCa cell with OG-PTX in the 
presence of multiple MRR 
inhibitors (40 μM FTC, 5 μM 
CsA and 40 μM FTC + 5 μM 
CsA), followed by adding 
anti-P-gp antibody. (c) Drug 
accumulation continued to 
rise in the WBC after 
treatment with DNR alone. 
No drug enhancement was 
observed after adding DNR in 
the presence of CsA. The 
WBC was not stained by anti-
P-gp antibody (anti-CD243). 
(d,e,f) The cell images were 
depicted before and after 
experiment, followed by 
adding trypan blue in PCa 
cells treated with DNR (d), 
OG-PTX (e) and WBC (f). DNR 
concentration was 35 μM. 
Scale bar: 20 μm. 
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CONCLUSIONS 
In this study, we demonstrated the applicability of an integrated microfluidic chip for the 
label-free isolation of prostate tumor (PCa) cells. The microfilter in Chamber 1 and DEP 
electrodes in Chamber 2  have the capability to achieve the isolation of single cancer cells from 
blood cells, as a model of CTC capture, as well as to preserve cell viability for subsequent drug 
accumulation measurement. Multiple experiments can then be conducted on the viable single cell 
to investigate the effect of MDR inhibitors on anticancer drug accumulation. FTC (as a well-
known ABCG2 inhibitor) and CsA (as a P-gp inhibitor) have been found to be effective in the 
enhancement of drug accumulation in the captured single PCa cells. The advantages of this 
integrated chip are the ability of fast isolation of PCa (<1 hr), of measuring drug accumulation 
(~1 hr) and of confirming the identity of the P-gp expressing cancerous cell. This new biochip 
requires a small number of cells to confirm the response of the cells to MDR inhibitors as 
compared to conventional methods, providing a potential for CTC research and for investigating 
multidrug resistance in CTCs. 
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